Moderna receives funding to accelerate mRNA-based influenza vaccine research.

$176 Million Grant Boosts Pandemic Flu Vaccine Development

The grant comes from the Rapid Response Partnership Vehicle Consortium (RRPV) funded by BARDA (Biomedical Advanced Research and Development Authority) under HHS (US Department of Health and Human Services).

US Government Invests in Public Health Preparedness

The funding supports development of a vaccine against the H5 avian influenza virus, known for causing severe illness in birds and potentially jumping to humans.

Targeting H5 Avian Influenza for Pandemic Prevention

This initiative goes beyond H5, exploring broader solutions for future public health emergencies.

Project Aims to Enhance Pandemic Response Capabilities

Launched in 2023, the trial assesses the safety and immune response of the mRNA-1018 vaccine candidate in adults against H5 and H7 avian influenza strains.

Moderna's Phase I/II Trial Tests mRNA-1018 Vaccine

Findings from the ongoing trial will be crucial for planning the next phase (Phase III) of the vaccine development process.

Trial Results Expected in 2024 to Guide Further Development

Moderna CEO Stéphane Bancel highlights the benefits of mRNA technology, including faster development, efficient production, and proven effectiveness against infectious diseases like COVID-19.

mRNA Technology Offers Advantages in Vaccine Development

Bancel emphasizes continued partnership with BARDA to expedite mRNA-based pandemic influenza vaccines and support global preparedness.

Moderna Committed to Collaboration for Global Health

The project is financed by federal funds provided by HHS, ASPR (Administration for Strategic Preparedness and Response), and BARDA.

US Government Funds This Important Initiative

Just in June 2024, Moderna's mRESVIA vaccine for respiratory syncytial virus (RSV) in adults 60 and older received FDA approval.

Moderna Receives FDA Approval for Another mRNA Vaccine